A new study published in the journal Neuron, conducted by Helene Tran, Ph.D. and Fen-Biao Gao, Ph.D., from the University of Massachusetts Medical School, provides insights in the pathogenic consequences of the most common genetic mutation causing ALS (Amyotrophic Lateral Sclerosis). ALS is an incurable and rapidly…
The ALS Association, the nation’s leading non-profit organization dedicated to addressing Lou Gehrig’s disease in both research initiatives and patient support services, recently announced the launch of new partnerships with several hospitals and academic institutions in a renewed effort to expand the accumulation of biofluids from patients with ALS, for the research…
The Northeast ALS Consortium (NEALS) Data and Safety Monitoring Board (DSMB) recently issued Synapse Biomedical Inc. a notice to suspend amyotrophic lateral sclerosis patient enrolment for a randomized control trial of diaphragm pacing. The suspension of new enrolment was not due to safety concerns, but as a response to the slow rate of patient…
Neuraltus Pharmaceuticals, Inc. recently announced it has partnered with the Clinigen Group plc’s Idis Managed Access (MA) division to launch a program for the former’s product candidate for amyotrophic lateral sclerosis (ALS), NP001. This agreement effectively makes the program available in several European territories, with an estimated growth to more countries as 2016…
The ALS Association, the country’s premier organization committed to find a cure for ALS and improving the lives of those affected by this rare disease, has just announced the viral and recently relaunched ALS Ice Bucket Challenge has played an integral role in pushing the creation of a new drug development…
Three prominent health institutions have recently come together to form the country’s largest coordinated and comprehensive initiative against amyotrophic lateral sclerosis (ALS). Last week, Johns Hopkins University’s Robert Packard Center for ALS Research, Cedars-Sinai Medical Center’s Regenerative Medicine Institute and the Massachusetts General Hospital Neurological Clinical Research Institute officially launched a joint…
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs for the treatment of cancer and other major diseases, recently announced the evaluation of its SINE nuclear transport compound KPT-350 as a treatment for Amyotrophic Lateral Sclerosis (ALS). Results from preclinical studies will…
Synapse Biomedical Inc., a company that commercializes the NeuRx Diaphragm Pacing System (DPS), has recently announced it will be presenting data on the company’s Post Approval Study (PAS), a multi-center trial that demonstrated DPS’s safety and survival benefit, during the 26th International Symposium on ALS/MND. Data will be presented by Dr. Robert Miller, Principal Investigator of the…
Portage Biotech, Inc. together with privately-held Biohaven Pharmaceutical Holding Company Ltd. has just acquired global intellectual property rights to an extensive 300-product portfolio by ALS Biopharma, LLC. These prodrugs included in the line up, most of which are classified as New Molecular Entities (NMEs), were originally designed and prepared by…
A new research collaboration was recently formed between Biogen Idec, the ALS Association and Columbia University Medical Center (CUMC) to study the differences and similarities in ALS’ disease progress and how an patient’s genes can influence its clinical manifestations. The joint research initiative, titled, “Genomic Translation for ALS Clinical care” (GTAC), will entail…
Get regular updates to your inbox.